The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 27, 2024
Filed:
Jan. 23, 2019
Applicant:
Gila Therapeutics, Inc., Minneapolis, MN (US);
Inventors:
Andres Acosta, Rochester, MN (US);
Thomas Vasicek, Minneapolis, MN (US);
Beth Anne-Szkudlarek Brown, Plymouth, MN (US);
Assignee:
Gila Therapeutics, Inc., Minneapolis, MN (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/22 (2006.01); A61K 9/00 (2006.01); A61P 3/04 (2006.01); A61K 47/38 (2006.01); A61K 9/48 (2006.01); A61K 9/20 (2006.01); A61K 47/02 (2006.01); A61K 9/16 (2006.01); A61K 47/26 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/46 (2006.01); A61K 9/68 (2006.01); A61K 47/32 (2006.01); A61K 9/19 (2006.01); A61K 47/18 (2017.01);
U.S. Cl.
CPC ...
A61K 38/22 (2013.01); A61K 9/006 (2013.01); A61K 9/0056 (2013.01); A61K 9/0058 (2013.01); A61K 9/0063 (2013.01); A61K 9/0075 (2013.01); A61K 9/1623 (2013.01); A61K 9/19 (2013.01); A61K 9/205 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01); A61K 47/46 (2013.01); A61P 3/04 (2018.01);
Abstract
Pharmaceutical compositions comprising PYY (e.g., PYY(3-36) and analogs and variants thereof), satiety peptides, satiety hormones, metabolic hormones, and methods of treating metabolic diseases with such compositions are provided. Aspects include methods of increasing a feeling of fullness in patients treated with pharmaceutical compositions comprising PYY, PYY(3-36), satiety peptides, satiety hormones, metabolic hormones, and analogs, receptor antagonists and variants thereof.